Li X, Liu C, Mao Z, et al. - Researchers conducted this systematic review and meta-analysis to test the safety and effectiveness of Polymyxin B-immobilized hemoperfusion [PMX-HP ; an innovative approach that was developed in Japan during the 1990s as one of the antiendotoxic strategies against sepsis] against sepsis or septic shock. Databases (PubMed, EMBASE and Cochrane Library) were searched to identify eligible randomized controlled trials (RCTs). Thirteen studies involving 1,163 patients have been identified. Findings suggested that the use of PMX-HP to treat patients with less severe sepsis will minimise overall mortality and is safe. The efficacy of the treatment can benefit from lowering the level of endotoxin and improving hemodynamics. To further evaluate the clinical function of PMX-HP against severe sepsis or septic shock, more high-quality RCTs are needed.